Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review

Research output: Contribution to journalReviewResearchpeer-review

As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.

Original languageEnglish
JournalAdverse Drug Reaction Bulletin
Volume339
Issue number1
Pages (from-to)1315-1318
Number of pages4
ISSN0044-6394
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.

ID: 344447603